Fu'an Pharmaceutical: Announcement on the subsidiary's intention to be selected for the continued procurement of varieties after the expiration of the national organization's collective drug purchase agreement
Securities code: 300194 Securities abbreviation: Fu'an Pharmaceutical Announcement number: 2026-005 Fu'an Pharmaceutical (Group) Co., Ltd.
Regarding the expired varieties of the subsidiary’s participation in the national organization’s centralized drug purchase agreement
Announcement of Proposed Successful Procurement
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and there are no false records, misleading statements or major omissions.
Fuan Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the "Company") wholly-owned subsidiaries Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd., Fuan Pharmaceutical Group Ningbo Tianheng Pharmaceutical Co., Ltd., Fuan Pharmaceutical Group Yantai Zhichu Pharmaceutical Co., Ltd., and Fuan Pharmaceutical Group Hubei People's Pharmaceutical Co., Ltd. recently participated in the national organization of centralized drug procurement 1-8 For the bidding work for the continuation procurement of varieties after the expiration of the batch agreement, according to the "Results of Proposed Continuation Procurement of Variety Expiration of the National Organized Collective Purchasing Drug Agreement" (LC-YPJX-2026-1) released by the Office for Continuation Purchasing of Variety Expired by the National Organization of Collective Purchasing Drug Agreement (hereinafter referred to as the "Continuation Procurement Office") on February 10, 2026, a total of 28 drug varieties of the company's subsidiaries are planned to be selected for this continuation procurement. The relevant information is now announced as follows:
1. Basic information of the drug to be selected
Serial number Name of the drug to be selected
Main Specifications Indications
1 Dexmedetomidine injection 2ml: 0.2mg is used for sedation during tracheal intubation and mechanical ventilation in surgical patients undergoing general anesthesia.
2.5 mg for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement 2 Apixaban oral sustained-release dosage form
parts (VTE).
3 Quetiapine oral sustained-release dosage forms 0.1g and 0.2g are used for the treatment of schizophrenia and the treatment of manic episodes in bipolar disorder.
5 mg for moderate to severe disease in which one or more TNF blockers are insufficiently effective or intolerable 4 Tofacitinib oral extended-release dosage form
Adult patients with highly active rheumatoid arthritis (RA).
Suitable for acute and chronic lung diseases associated with abnormal sputum secretion and poor sputum excretion function 2ml: 15mg
Preventive treatment of pulmonary complications after disease and surgery. Infant Breathing of Premature Infants and Newborns 5 Ambroxol Injection
4ml:30mg Treatment of distress syndrome (IRDS).
10ml:0.1g Breathing difficulty caused by bronchial asthma, chronic asthmatic bronchitis and other bronchospasm 6 Doxofylline Injection
Difficult.
Levofloxacin Oral Sustained Release 0.5g can be used to treat mild, moderate and severe infections in adults (≥18 years old) caused by sensitive strains of bacteria.
40 mg As an alternative treatment for gastroesophageal reflux disease, acute gastric or duodenal ulcer bleeding in patients at low risk for duodenal ulcer bleeding in adults, for the reduction of gastric and duodenal ulcer bleeding in adults
Risk of rebleeding after endoscopic treatment.
100ml: 35g (I) X-ray contrast agent. Can be used for cardiovascular angiography, arteriography, urography, venography,
Enhanced CT examination; cervical, thoracic and lumbar spinal canal angiography, CT after transspinal subarachnoid injection 9 Iohexol injection 100ml: 30g (I)
cisternography; arthrography, etc.
50ml: 17.5g (I)
10 Lercanidipine oral sustained-release dosage form 10 mg is used to treat mild to moderate essential hypertension.
11 Lipoic acid injection 12ml:0.3g Sensory abnormalities caused by diabetic peripheral neuropathy.
5ml:0.25mg For adults to prevent acute nausea and vomiting caused by highly emetogenic chemotherapy. Preventing moderate emesis 12 Palonosetron injection
Acute and delayed nausea and vomiting caused by chemotherapy
0.75g is used to treat infections caused by specific susceptible strains of microorganisms in the following diseases: respiratory infections, ear, nose and throat infections, urinary tract infections, skin and soft tissue infections, sepsis, meningeal infections 1.5g
inflammation, gonorrhea, bone and joint infections, puerperal and gynecological infections, etc.
14 Ceftazidime injection 0.5g, 1.0g is used to treat single or multiple infections caused by sensitive microorganisms.
20ml:0.5g For the treatment or prevention of infections proven or highly suspected to be caused by susceptible bacteria. Including medical 15 Levofloxacin Injection hospital-acquired pneumonia, community-acquired pneumonia, acute bacterial sinusitis, chronic bronchitis
Acute bacterial attacks of inflammation, etc.
16 Ondansetron injection 4ml:8mg is used to control nausea and vomiting caused by cancer chemotherapy and radiotherapy; also suitable for prevention and treatment
Treat nausea and vomiting after surgery.
1ml: 0.1mg Control 17 symptoms of acromegaly and reduce growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in patients with acromegaly whose disease cannot be adequately controlled by surgery or radiation therapy.
plasma levels.
2.5ml: 25mg auxiliary drug for general anesthesia, used for tracheal intubation during routine induction of anesthesia and maintenance surgery 18 Rocuronium Bromide Injection
Neuromuscular blockade of mid-skeletal muscles.
19 Methylprednisolone injection 20mg, 40mg is used for anti-inflammatory treatment, immunotherapy, rheumatic diseases, skin diseases, etc. 20 Cefmetazole Injection 0.5g, 1.0g is used to treat infections caused by bacteria that are sensitive to cefmetazole sodium.
21 Cefminox injection 0.5g, 1.0g is used to treat various infections that are sensitive to cefminox.
22 Tigecycline Injection 50mg is used for infections caused by susceptible strains of certain bacteria.
5ml:0.5g For the treatment of epilepsy, in adults and children when oral dosage forms cannot be taken temporarily, 23 Sodium Valproate Injection
As an alternative to oral dosage forms.
3mg for severe acute esophageal variceal bleeding. Severe acute gastric or duodenal ulcer 24 somatostatin injection
blood, or complicated by acute erosive gastritis or hemorrhagic gastritis, etc.
25 Aztreonam Injection 0.5g, 1.0g is used to treat infections caused by sensitive Gram-negative bacteria
It is used to treat fungal infections in adults and children aged 2 years and above. Including invasion 0.2g
26 voriconazole injection
Aspergillosis, candidemia, etc.
1.125g, 2.25g Used for the treatment of community-acquired pneumonia, hospital-acquired pneumonia, urinary tract infection, and intraluminal infection. Piperacillin-tazobactam injection
Moderate to severe infections caused by susceptible isolates of specified bacteria in conditions such as infectious diseases. agent
4.5g
0.75g, 1.5g Anti-infective drugs, used to treat upper and lower respiratory tract infections caused by sensitive bacteria, gallbladder 28 Cefoperazone Sulbactam Injection (2:1) 1.0g, inflammation, sepsis, meningitis, etc.
1.5g, 2.0g (1:1)
Note: The proposed purchasing quantities and proposed winning prices of the above varieties are subject to the final data released by the Procurement Office.
2. The impact of the products to be selected this time on the company
The total sales of the 28 drug varieties to be selected by the company's subsidiaries in 2024 will be 679.9328 million yuan, accounting for 28.43% of the company's operating income in 2024; the total sales of the above-mentioned products to be selected in the first three quarters of 2025 will be 329.4377 million yuan (unaudited), accounting for 25.05% of the company's operating income in the first three quarters of 2025.
This continued purchase is the continued purchase of varieties after the expiration of the national organization's centralized drug purchase agreement. The agreed purchase volume is based on the demand for each enterprise's purchase variety filled in by the pharmaceutical institution, and the proportion of the quantity is determined according to the selected price gradient. The procurement cycle starts from the actual implementation date of the winning results to December 31, 2028. During the procurement cycle, medical institutions will give priority to the selected drugs for this subsequent purchase and ensure that the agreed purchase volume is completed. The procurement office will then calculate the agreed purchase volume based on the proportion of each selected drug variety. The remaining portion after adjustment of the agreed purchase volume of each selected drug shall be selected by the pharmaceutical institution among the selected companies whose declared prices are not higher than the inquiry benchmark; after the pharmaceutical institution confirms the agreed purchase volume, the procurement office will then release the results to the selected company. The purchase quantity and price of the selected varieties to be selected are subject to the final data released by the procurement office. If the above-mentioned products to be selected are subsequently signed and implemented with purchase contracts, it will help the company's products increase their market share and have a positive impact on the company's future business development.
3. Risk warning
The results of the above-mentioned products to be selected need to be confirmed after no objection is announced. The supply area and quantity of the products to be selected have not yet been confirmed. Subsequent matters such as the signing of the procurement contract are still uncertain. Pharmaceutical production and sales are affected by changes in national policies, bidding and procurement, changes in the market environment and other factors, and there is a certain degree of uncertainty. Investors are advised to make prudent decisions and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Fu'an Pharmaceutical (Group) Co., Ltd.
February 12, 2026